Navigation Links
Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:6/16/2008

HAYWARD, Calif., June 16 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.

The randomized, double-blind study is designed to assess the drug's effect on dyslipidemia and insulin resistance, and will evaluate two different doses of MBX-8025 given over an 8-week period, both alone and in combination with Lipitor(R) (atorvastatin). The primary endpoint is the reduction in Apo B-100, the atherogenic lipoprotein in LDL (low-density lipoprotein), compared to placebo. Secondary endpoints include measurements of the effect of treatment on LDL, HDL (high-density lipoprotein), triglycerides and body weight and composition. Metabolic parameters, including glucose and insulin levels and insulin sensitivity, are also being assessed.

"America is suffering from an epidemic of obesity and its consequences, one of which is mixed dyslipidemia. Patients with this type of dyslipidemia have elevated LDL cholesterol, but also have elevated triglycerides, low HDL levels, and have a large amount of small, dense LDL particles, which are much more atherogenic," said David B. Karpf, M.D., the chief medical officer of Metabolex. "Statins do a good job of lowering LDL, but are not fully effective because they do not treat the other aspects of mixed dyslipidemia. This enrollment milestone puts us one step closer to understanding the ability of MBX-8025 to treat mixed dyslipidemia, as well as providing preliminary evidence of the drug's ability to enhance insulin sensitivity and reduce body weight -- two additional features of metabolic syndrome."

About Dyslipidemia

A growing body of research indicates that cardiac risk is affected by a number of different compounds in the blood,
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Initiates Phase 1 Trial of MBX-2982
2. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. Pharmaxis Long-Term Safety Study of Bronchitol Completes
5. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
6. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 /PRNewswire/ ... the appointments of Dr. Ashraf Hanna , M.D., ... to its Board of Directors. Dr. Hanna is the ... Genentech and Chief Financial Officer for the Genentech Foundation, ... and Global Head of Business Development and Licensing for ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
(Date:9/18/2014)... /CNW/ - A new expert panel report, Improving Medicines ... released today by the Council of Canadian Academies, addresses ... children. Each year about half of Canada,s ... prescription drug. Much of this prescribing is done off-label ... potential health risks. Children have historically been ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... publication in prominent peer-reviewed journal highlights,findings of ... infection, EVANSTON, Ill., March 17 ... using a,rapid molecular diagnostic test is effective ... published in the Annals of Internal Medicine,by ...
... on Track to Initiate Phase 2b in Second Quarter ... - Conference Call Tomorrow at 8:00 a.m. ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced positive ... RDEA806, its novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients ...
Cached Medicine Technology:Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 2Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
(Date:9/18/2014)... By Randy Dotinga ... -- Women who have the largest number of post-traumatic stress ... an addiction to food, a new study suggests. ... women overeating or becoming addicted to food. And it,s also ... experiencing trauma, PTSD, or both. Still, the research ...
(Date:9/18/2014)... 18, 2014 How much is a ... of the factors contributing to the obesity epidemic in ... single serving and how to manage portion size during ... Oct. 3 at Humility House, 755 Ohltown Road, Austintown. ... lead the informational discussion and answer questions from 12:30 ...
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is proud to ... Association (HPA) Friends and Family Golf tournament on ... tournament, which will take place at TopGolf from 9 ... through three golf challenges, “Top Scramble”, “Top Score”, and ... provided at the event and there will be open ...
(Date:9/18/2014)... Eye doctors have long known that staring ... basal tear film in the eyes to lose water and ... that staring at a computer screen can also alter the ... about computers, the tear film and dry eye for years ... (*Gray, Sarah, “Staring at Screen is Altering Your Tears, Study ...
(Date:9/18/2014)... 18, 2014 Members of United ... participating network dentists at UnitedConcordia.com, thanks to a ... company. , "Members can book an appointment with ... button located on the Find a Dentist page ... of network operations at United Concordia. "We are ...
Breaking Medicine News(10 mins):Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:HMHP Workshop Addresses Portion Control 2Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 3Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3
... , , LEXINGTON, Ky., Sept. ... stopping in Kentucky throughout the week of September 8 - 11 ... access information on programs that provide prescription medicines for free or ... -- one of the worst rates in the nation -- the ...
... BATESVILLE, Ind., Sept. 4 Hill-Rom Holdings, Inc. (NYSE: ... $0.1025 per share. This dividend was declared by Hill-Rom,s Board of ... to shareholders of record as of September 16, 2009. , , ... is a leading worldwide manufacturer and provider of medical technologies and related ...
... , , , DETROIT, Sept. ... Daniel J. Loepp made the following statement in conjunction with the ... with a serious illness. , , Blue Cross ... to jointly announce Mr. Harwell,s retirement as Blue Cross,s health and ...
... , , , ... Dk hybrid contact lens manufacturer, recently introduced a new ... revolutionary contact lens that takes advantage of the best ... centration, stability, and all-day comfort. The patent-pending design is ...
... , NEW HAVEN, Conn., Sept. 4 ... development and commercialization of novel antibiotics for the treatment of ... has joined the company as Chief Business Officer. In his ... activities. , , Mr. Kassberg, age 49, ...
... , NEW YORK, Sept. 4 Delcath Systems, ... its proprietary treatment method for primary and metastatic cancers to the ... make a presentation to investors at the Rodman & Renshaw 11th ... Time in New York. Mr. Hobbs will review the Company,s business ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 3Health News:SynergEyes, Inc. Expands Launch of New Hybrid Contact Lens Design for Keratoconus Patients 2Health News:Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer 2
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... precise control of the thigh during varus/valgus manipulation ... the proximal thigh during ACL or PCL procedures. ... on both right and left legs and may ... Holder can be used with an Arthrex tourniquet ...
... for trauma, foot and ankle or deformity ... External Fixation components are designed to reduce ... the complexity of intra-operative and post-operative frame ... and hinges eliminate the need to stock ...
Medicine Products: